{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:33:48Z","timestamp":1793414028537,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI208808"],"award-info":[{"award-number":["WI208808"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin\u2010dependent kinase 4\/6 (CDK4\/6) inhibitors, including palbociclib, are approved to treat hormone receptor (HR)\u2010positive\/human epidermal growth factor receptor 2 (HER2)\u2010negative advanced breast cancer (ABC) and are associated with hematologic toxicity. African American women, who are underrepresented in CDK4\/6 inhibitor clinical trials, may experience worse neutropenia because of benign ethnic neutropenia. The authors specifically investigated the hematologic safety of palbociclib in African American women with HR\u2010positive\/HER2\u2010negative ABC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PALINA was a single\u2010arm, open\u2010label, investigator\u2010initiated study of palbociclib (125 mg daily; 21 days on and 7 days off) plus endocrine therapy (ET) in African American women who had HR\u2010positive\/HER2\u2010negative ABC and a baseline absolute neutrophil count \u22651000\/mm\n                      <jats:sup>3<\/jats:sup>\n                      (ClinicalTrials.gov identifier NCT02692755). The primary outcome was the proportion of patients who completed 12 months of therapy without experiencing febrile neutropenia or treatment discontinuation because of neutropenia. Single nucleotide polymorphism analysis was used to assess Duffy polymorphism status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010five patients received \u22651 dose of palbociclib plus ET; 19 had a Duffy null polymorphism (cytosine\/cytosine). There were no reports of febrile neutropenia or permanent study discontinuation because of neutropenia. Significantly more patients with the Duffy null versus the wild\u2010type variant had grade 3 and 4 neutropenia (72.2% vs 23.1%;\n                      <jats:italic>P<\/jats:italic>\n                      = .029) and required a palbociclib dose reduction (55.6% vs 7.7%;\n                      <jats:italic>P<\/jats:italic>\n                      = .008). Patients with the Duffy null versus the wild\u2010type variant had lower overall relative dose intensity (mean \u00b1 SD, 81.89% \u00b1 15.87 and 95.67% \u00b1 5.89, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      = .0026) and a lower clinical benefit rate (66.7% and 84.6%, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that palbociclib is well tolerated in African American women with HR\u2010positive\/HER2\u2010negative ABC. Duffy null status may affect the incidence of grade 3 neutropenia, dose intensity, and possibly clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.33620","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T18:51:58Z","timestamp":1624387918000},"page":"3622-3630","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer"],"prefix":"10.1002","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"Filipa","family":"Lynce","sequence":"first","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine Georgetown University Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Washington Cancer Institute MedStar Washington Hospital Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olwen M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysa","family":"Abu\u2010Khalaf","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center at Jefferson Health Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Mohebtash","sequence":"additional","affiliation":[{"name":"MedStar Franklin Square Cancer Center Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianmin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Bioinformatics, and Biomathematics Georgetown University Medical Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Dilawari","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"},{"name":"Washington Cancer Institute MedStar Washington Hospital Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti R.","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Washington Cancer Institute MedStar Washington Hospital Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Chitalia","sequence":"additional","affiliation":[{"name":"Washington Cancer Institute MedStar Washington Hospital Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Warren","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Bioinformatics, and Biomathematics Georgetown University Medical Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha N.","family":"Shajahan\u2010Haq","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center and Georgetown Lombardi Comprehensive Cancer Center Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1487"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05528-2"},{"key":"e_1_2_8_5_1","volume-title":"IBRANCE\u00ae capsules (palbociclib). Full prescribing information","author":"Pfizer Inc","year":"2019"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy109"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05134-x"},{"key":"e_1_2_8_10_1","first-page":"1","article-title":"Palbociclib plus letrozole as first\u2010line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA\u20102 study","volume":"5","author":"Im SA","year":"2019","journal-title":"J Glob Oncol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.008318"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21583"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3881"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb01192.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15730"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000360"},{"key":"e_1_2_8_21_1","volume-title":"Blood Groups and Red Cell Antigens","author":"Dean L","year":"2005"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.05.012"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-131"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0019"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0097"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.1427.3.11"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:00:41Z","timestamp":1760302841000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/cncr.33620"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33620","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"2020-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}